Navigation Links
Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
Date:9/2/2010

SAN DIEGO, Sept. 2 /PRNewswire/ -- Results from studies related to Optimer Pharmaceuticals, Inc.'s (Nasdaq: OPTR) lead developmental product candidate, fidaxomicin, will be presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held at the Boston Convention and Exhibition Center in Boston on September 12-15, 2010.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Fidaxomicin abstracts and speakers include:"Randomized Controlled Trial (RCT) of Fidaxomicin (FDX) Versus Vancomycin (VAN) in Treatment of Recurrent Clostridium difficile Infection (CDI)"Oral Presentation: Oliver Cornely, M.D.

Tuesday, September 14, 2010 9:00 am - 9:15 am Eastern Time

Presentation number: L1-1305 in 253A

"Clostridium difficile Strain Type as Determined by Restriction Endonuclease Analysis (REA) Typing in Two Phase III Trials of Fidaxomicin vs Vancoymcin: Treatment Outcome for the Epidemic BI/NAP1/027 Strain"Oral Presentation: Dale N. Gerding, M.D.

Tuesday, September 14, 2010 9:15 am - 9:30 am Eastern Time

Presentation number: L1-1306 in 253A

"Correlation of the ATLAS Bedside Scoring System And Its Components With Cure and Recurrence of Clostridium difficile Infection (CDI)"Poster Presentation: Mark A. Miller, M.D.

Tuesday, September 14, 2010 11:15 am - 1:15 pm Eastern Time

Presentation number: K-1692 in Exhibit Hall B1

"Use of Concomitant Antibiotics (CA) Has a Deleterious Effect on Outcomes During Treatment for Clostridium difficile Infection (CDI)"Poster Presentation: Kate Mullane, M.D.

Tuesday, September 14, 2010 11:15 am - 1:15 pm Eastern Time

Presentation number: K-1695 in Exhibit Hall B1

"Comparative Susceptibilities of Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence and Failure from Patients in a Phase III trial (004) of C difficile infection (CDI)"Poster Presentation: Ellie J. Goldstein, M.D.

Tuesday, September 14, 2010 11:15 am - 1:15 pm Eastern Time

Presentation number: K-1691 in Exhibit Hall B1

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI).  In two Phase 3 trials completed by Optimer to study the safety and efficacy of fidaxomicin for the treatment of CDI, fidaxomicin was statistically superior to vancomycin in global cure rate (defined as cure with no recurrence within four weeks of completing therapy) as well as statistically superior in reducing recurrences of CDI by up to 50% when compared with vancomycin, the only FDA approved product for CDI. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea.  Optimer has also successfully completed two Phase 3 trials with Pruvel.  Additional information can be found at http://www.optimerpharma.com.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale Communications, Inc.Jason I. Spark, Senior Vice President619-849-6005
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
2. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
3. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
4. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
5. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
6. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
7. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
8. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
9. Pfizer to Acquire FoldRx Pharmaceuticals
10. Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China
11. Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Association, in partnership with ALS Finding a Cure, is pleased ... track TDP43 aggregation. The successful team(s) with the most developed ... --> --> ALS is ... brain and the spinal cord. Eventually, people with ALS lose ... leads to total paralysis and death within two to five ...
(Date:2/10/2016)... Feb. 10, 2016 Convergence scenarios ... of various technologies that results in diverse ... These opportunities create a cyclical system where ... drives the development of new technologies. ... by technology convergences, which are constantly fostering ...
(Date:2/10/2016)... 10, 2016 Antibacterial Drugs Market - ... - 2023 ", reveals that the global antibacterial drugs market ... to 2023 owing to patent expiries of blockbuster drugs. Even ... during the forecast period, the value is anticipated to decline ... --> Antibacterial Drugs Market - Global Industry Analysis, ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing ... February 2016. Each webinar features a dynamic expert and thoughtful presentation to give ... patients and facilities. Both events are free to attend, but registration is ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... American Academy of Emergency Medicine , an emergency medicine professional association, ... practice management services . , The American Academy of Emergency Medicine, or AAEM, ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency in ... assist the local community. Pledging to select a new beneficiary every 60 days, ... area. Their goal is to bring community awareness to important local causes by ...
(Date:2/10/2016)... , ... February 10, 2016 , ... 10 Best ... There were three leading bottled water brand owners that topped the list as a ... connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch water ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of ... is now accepting new dental patients and families in the North Metro Denver area. ... services from cleanings to cosmetic dentistry, and all in the most relaxing environment. , ...
Breaking Medicine News(10 mins):